monoclonal antibody. fortunately, the gsk, their product, looks like it s well positioned to be used as a treatment against omicron, and the az product also is likely. small molecule antivirals are available now. you heard the recent approval of an eua of paxlovid. of note, and under appreciated, remdesivir is already fully approved and is available in a three-day course, which in a recent study shown to dramatically diminish the need for hospitalization. guidelines on this will be now re-examined by the nih guidelines committee and you ll be hearing more about recommendations, how to utilize these. if i can have the last slide. i want to, again, just reiterate what dr. walensky said about prevention, which is a
work against omicron and those are shown in the first two monoclonal antibody. well positioned to be used as a treatment against omicron and then the az product also is likely. small molecule antivirals are available now. you heard the recent approval of an eua of paxlovid and available in a three-day course which in a recent study shows to diminish the need for hospitalization. guidelines on this will be now reexamined by the nih guideline committee and you ll be hearing more about recommendations on how to utilize these. if i can have the last slide. i want to reiterate what dr. wolensky said about prevention which is a multi-layered comprehensive process. the hallmark of which is